Please read the details through this link: https://www.bioworld.com/articles/432589-tennors-prosthetic-joint-infections-therapy-tnp-2092-set-to-start-phase-iii-soon?v=preview
SUZHOU, China, Jan. 20, 2020 /PRNewswire/ -- TenNor Therapeutics, a clinical-stage, global biopharmaceutical company has received FDA Orphan Drug Designation for TNP-2092 to treat prosthetic joint infections.
TenNor publishes article on TNP-2092 PO Potential Application in the Treatment of Gastrointestinal and Liver Disorders in ACS Infectious Disease. Please read the article through this link：https://pubs.acs.org/doi/abs/10.1021/acsinfecdis.9b00374